
NJ-based CytoSorbents Corp. innovates blood purification tech for acute and chronic health issues.
CytoSorbents Corp., based in Monmouth Junction, New Jersey, is dedicated to the research, development, and commercialization of medical devices centered around its innovative blood purification technology. The company's core mission is to address acute and chronic health complications related to blood toxicity. CytoSorbents aims to provide effective solutions for various medical applications, enhancing patient outcomes through advanced blood purification methods.
CytoSorbents has made significant strides in the medical field with its proprietary technology, which has been applied to treat a range of conditions associated with blood toxicity. The company has gained recognition for its impactful contributions to healthcare, improving the quality of life for patients with severe health issues. Through continuous innovation and development, CytoSorbents has established itself as a key player in the medical device industry.

SeaStar Medical

Immutrix Therapeutics
immutrix.com

Halcyon Biomedical

Path EX
pathex.co

Cerus

Aethlon Medical
aethlonmedical.com

Sanguis
sanguiswine.com

EndoShunt Medical
endoshunt.com

Haemonetics
haemonetics.com

Innovative Trauma Care

BiomedInnovations

Concept Medical
conceptmedical.com

Nephros
nephros.com

AngioDynamics
angiodynamics.com

TransMedics
transmedics.com
Companies similar to CytoSorbents include SeaStar Medical, Immutrix Therapeutics, Halcyon Biomedical and Path EX.
CytoSorbents was founded in 2014.
CytoSorbents' headquarters is located in Monmouth Junction, NJ, US.
CytoSorbents' most recent funding round was for $10.3M (USD) in December 2023.
As of Dec 13, 2023, CytoSorbents has raised a total of $39.8M (USD).
CytoSorbents has 198 employees as of Feb 6, 2024.